UTC Therapeutics Inc.

Zhengzhou, Henan

OncologyCAR-TPhase I

Compare Sign in to watch

What changed

NIH R35 · $0.4M · Computational methods for sub-cellular spatial transcriptomics with high gene coverage

3mo agoNew grantApr 7, 2026Source filing (opens the source filing in a new tab)

Momentum

86no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R35 · $444k · non-dilutive
May 1, 2026
DUKE UNIVERSITY · PI ZHANG, YI · NIGMS · award ends Feb 28, 2031 · Computational methods for sub-cellular spatial transcriptomics with high gene coverage
NIH RePORTER · NIH RePORTER 11269831 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 1, 2025
Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione · RECRUITING · sponsor: The First Affiliated Hospital of Zhengzhou University · Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
ClinicalTrials.gov · NCT06896422 (opens the source filing in a new tab)
Grant
R01 · $761k · non-dilutive
Apr 5, 2025
BOSTON CHILDREN'S HOSPITAL · PI ZHANG, YI · NICHD · award ends Jan 31, 2030 · Understanding the mechanism of pre- to naïve- to formative- pluripotency transitions
NIH RePORTER · NIH RePORTER 11312675 (opens the source filing in a new tab)
Trial
NA registered
Apr 3, 2025
HER2-positive Advanced Malignant Solid Tumors · RECRUITING · sponsor: UTC Therapeutics Inc. · Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
ClinicalTrials.gov · NCT06658951 (opens the source filing in a new tab)
Trial
NA registered
Mar 21, 2024
Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention · RECRUITING · sponsor: Yi Zhang · Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
ClinicalTrials.gov · NCT06198517 (opens the source filing in a new tab)
Trial
NA registered
Mar 1, 2024
Dry Eye Disease · ENROLLING_BY_INVITATION · sponsor: Tianjin Eye Hospital · Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom
ClinicalTrials.gov · NCT07171710 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.44same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R35 · $0.4M · Computational methods for sub-cellular spatial transcriptomics with high gene coverage
3mo agoNew grantSource (opens the source filing in a new tab)
Study registered, no phase assigned: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
4mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Understanding the mechanism of pre- to naïve- to formative- pluripotency transitions
6mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
11mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
11mo agoTrial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R35 · $444k · non-dilutive

PHASE1 registered

R01 · $761k · non-dilutive

NA registered

NA registered

NA registered